Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK StudyRachael F. Grace, Bertil Glader, D. Mark Layton et al.|Blood|2019Cited by 3
225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skippingL. De Waele, M. Guglieri, Perry B. Shieh et al.|Neuromuscular Disorders|2024Cited by 1
Safety and Efficacy of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping (S31.010)Perry B. Shieh, Michela Guglieri, Craig Campbell et al.|Neurology|2025Cited by 0